By Fineline Cube 
German pharmaceutical giant Bayer’s (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the initiation of a Phase I clinical study for its investigational RAS-PI3Kα inhibitor, VVD-159642. This marks a significant step forward in the development of targeted therapies for RAS-driven cancers.’
Clinical Trial Details
The Phase I study (NCT06804824) is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-159642. The trial will assess the drug both as a single agent and in combination with sotorasib or trametinib in patients with advanced solid tumors.
Therapeutic Potential
VVD-159642 represents a novel approach to targeting the RAS pathway, which is frequently mutated in various cancers. By inhibiting both RAS and PI3Kα, the drug aims to enhance therapeutic efficacy and overcome resistance mechanisms commonly observed in RAS-driven malignancies.-Fineline Info & Tech